Navigation Links
Amsterdam Molecular Therapeutics Licenses Additional Novel Gene Therapy Vectors from National Institutes of Health
Date:9/5/2011

e and need to patients of the other gene therapy programs."

About Amsterdam Molecular Therapeutics

AMT is a world leader in the development of human gene based therapies. The company's lead product Glybera®, a gene therapy for lipoprotein lipase deficiency (LPLD), is currently under review by the European Medicines Agency (EMA). If approved, Glybera will be the first gene therapy product to be marketed in Europe. AMT also has a product pipeline of several gene therapy products in development for hemophilia B, Duchenne muscular dystrophy, acute intermittent porphyria, Parkinson's disease and SanfilippoB. Using adeno-associated viral (AAV) derived vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate probably the world's first stable and scalable AAV manufacturing platform. This proprietary platform can be applied to a large number of rare (orphan) diseases caused by one faulty gene and allows AMT to pursue its strategy of focusing on this sector of the industry.  AMT was founded in 1998 and is based in Amsterdam. Further information can be found at http://www.amtbiopharma.com.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of AMT only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results coul
'/>"/>

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
2. Amsterdam Molecular Therapeutics Reports Full Year Results 2008
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
4. The University of Amsterdam Joins the MetaMiner Metabolic Diseases Project
5. Amsterdam Molecular Therapeutics Reports Full Year Results 2009
6. Amsterdam Molecular Therapeutics Reports Half-Year Results 2010
7. Amsterdam Molecular Therapeutics Successfully Lowers Cholesterol In Vivo With Enhanced Novel MicroRNA AAV Gene Therapy
8. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
9. Amsterdam Molecular Therapeutics Files Glybera® European Marketing Application for Re-examination
10. Amsterdam Molecular Therapeutics Reports Half-Year Results 2011
11. Molecular sleuths track evolution through the ribosome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... meal if certain protein components are experimentally disrupted, a ... discovered. The approach could be used as an ... diseases like dengue fever, yellow fever and malaria. ... vesicle transport, on which the mosquitoes rely to release ...
... on the buttock or the delicately soft entry of a blood ... "how" to use those tiny "molecular syringes" which are carbon nanotubes. ... (nanometre) and a maximum length of just a few millimetres, the ... ethereal tubes - the smallest ever made by man - is ...
... LOS ANGELES, July 18, 2011 Genesis Biopharma, Inc. ... today announced it has named David Voyticky to its ... Miller Energy Resources (NYSE: MILL ), an ... 16 years of experience in corporate finance and merger ...
Cached Biology Technology:Making blood-sucking deadly for mosquitoes 2Making blood-sucking deadly for mosquitoes 3Making blood-sucking deadly for mosquitoes 4Nanotech: injections or sampling? New 'molecular syringes' under testing 2Genesis Biopharma Names David Voyticky to Board of Directors 2
(Date:11/21/2014)... 19, 2014  Earlier this year Donald Spector ... and one of the most prolific inventors in the ... transmitted from Smartphones to third party agencies. Spector envisioned ... one of the earliest known patents in this area. ... the military, child care, elder care and hospital applications. ...
(Date:11/21/2014)... Nov. 20, 2014   Atmel® Corporation (NASDAQ: ... (MCU) and touch technology solutions, today launched the industry,s ... with the widest V cc range from 1.7V ... and faster I 2 C bus communication speeds, and ... memory making them ideal for consumer, industrial, computer, and ...
(Date:11/18/2014)... BETHESDA, Md. , Nov. 17, 2014 The ... European and U.S. regulatory agencies will speak and at least ... Quality Metrics Conference at the Omni Shoreham Hotel in ... is pleased once again to have significant support from the ... and Europe in our effort to ...
Breaking Biology News(10 mins):Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2
... ... N.Y. and FOOTHILL RANCH, Calif., Dec. 17 IBM ( ... new security solution that integrates palm vein biometric technology from Fujitsu ... http://www.newscom.com/cgi-bin/prnh/20091217/NY27736 ) , (Logo: http://www.newscom.com/cgi-bin/prnh/20090416/IBMLOGO ) , The ...
... has announced the winners of its student travel award ... the Moscone Convention Center in San Francisco, California, February ... selected based on scientific merit, with priority given to ... Each awardee receives a travel grant and will ...
... Athletes, superstitions and rituals can help them get ... non-steroidal anti-inflammatory drugs (NSAIDs), which many athletes gobble down ... harm than good. "These agents are treatments for ... says Stuart Warden, whose research at Indiana University focuses ...
Cached Biology News:Fujitsu and IBM Offer Biometric Security Solution That Replaces Passwords With the Scan of an Employee's Palm 2Fujitsu and IBM Offer Biometric Security Solution That Replaces Passwords With the Scan of an Employee's Palm 3Fujitsu and IBM Offer Biometric Security Solution That Replaces Passwords With the Scan of an Employee's Palm 4Fujitsu and IBM Offer Biometric Security Solution That Replaces Passwords With the Scan of an Employee's Palm 5Biophysical Society announces winners of 2010 Student Travel Awards 2Biophysical Society announces winners of 2010 Student Travel Awards 3Biophysical Society announces winners of 2010 Student Travel Awards 4NSAIDs: Take 'em early and often when competing? Think again 2
... ProteinChip System, Series 4000 incorporates the critical ... and biologists in biomarker research. The Series ... route for converting biomarker discoveries to biomarker ... Series 4000 is designed to fit into ...
Gelatin 100 mm Culture Dishes...
BD Primaria 100 mm Cell Culture Dish, surface-modified polystyrene for enhanced cell culture. (200/ca) Packaging: 20 / sleeve, 200 / case ...
...
Biology Products: